Rethinking herpes simplex virus: The way to oncolytic agents

Reviews in Medical Virology

Volumn 21, Issue 4, 2011, Pages 213-226

  Campadelli Fiume, Gabriella ^a   De Giovanni, Carla ^a   Gatta, Valentina ^a   Nanni, Patrizia ^a   Lollini, Pier Luigi ^a   Menotti, Laura ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DEOXYRIBONUCLEOTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; G 207; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HSV 1716; INTERLEUKIN 12; INTERLEUKIN 2; IRINOTECAN; LAPATINIB; M 103; NV 1020; ONCOLYTIC HERPES VIRUS; ONCOLYTIC VIRUS; PROTEIN KINASE R; RIBONUCLEOTIDE REDUCTASE; RRP 450; TRASTUZUMAB; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL THERAPY; BRAIN TUMOR; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; COLORECTAL CANCER; DRUG FEVER; ENZYME ACTIVITY; FLU LIKE SYNDROME; GLIOBLASTOMA; HEAD AND NECK CANCER; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HUMAN; LIVER CANCER; LIVER METASTASIS; MEASLES VIRUS; MELANOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PANCREAS CANCER; RECURRENT CANCER; REVIEW; SKIN TUMOR; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENE DELETION; GENETIC ENGINEERING; HERPESVIRUS 1, HUMAN; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RECEPTOR, ERBB-2; VIRAL PROTEINS; VIRAL TROPISM;

EID: 79959699571     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.691     Document Type: Review

References (76)

1. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Molecular Therapy 2007; 15: 651-659.
2. Hall SS. A Commotion in the Blood: Life, Death, and the Immune System. The Sloan Technology Series. Henry Holt and Company: New York, 1997.
3. Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nature Reviews. Microbiology 2008; 6: 529-540.
4. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 854-856.
5. Wong RJ, Chan MK, Yu Z, et al. Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12. Clinical Cancer Research 2004; 10: 251-259.
6. Varghese S, Rabkin SD, Nielsen GP, MacGarvey U, Liu R, Martuza RL. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Research 2007; 67: 9371-9379.
7. Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Therapy 2003; 10: 292-303.
8. Prestwich RJ, Errington F, Diaz RM, et al. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Human Gene Therapy 2009; 20: 1119-1132.
9. Hu JC, Coffin RS, Davis CJ, et al. A phase I study of oncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clinical Cancer Research 2006; 12: 6737-6747.
10. Veerapong J, Bickenbach KA, Shao MY, et al. Systemic delivery of (gamma 1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity. Cancer Research 2007; 67: 8301-8306.
11. Fong Y, Kim T, Bhargava A, et al. A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Molecular Therapy 2009; 17: 389-394.
12. Cassady KA, Gross M, Roizman B. The second-site mutation in the herpes simplex virus recombinants lacking the gamma 1 34.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha. Journal of Virology 1998; 72: 7005-7011.
13. Nakao A, Kimata H, Imai T, et al. Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer. Annals of Oncology 2004; 15: 988-989.
14. Chou J, Kern ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 1 34.5, a gene nonessential for growth in culture. Science 1990; 250: 1262-1266.
15. Whitley RJ, Kern ER, Chatterjee S, Chou J, Roizman B. Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models. Journal of Clinical Investigation 1993; 91: 2837-2843.
16. Karrasch M, Gillespie GY, Braz E, et al. Treatment of recurrent malignant glioma with G207, a genetically engineered herpes simplex virus-1, followed by irradiation: Phase I results. Journal of Clinical Oncology (ASCO Meeting Abstract) 2009; 27: 2042.
17. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Therapy 2000; 7: 867-874.
18. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Medicine 1995; 1: 938-943.
19. Markert JM, Gillespie GY, Weichselbaum RR, Roizman B, Whitley RJ. Genetically engineered HSV in the treatment of glioma: a review. Reviews in Medical Virology 2000; 10: 17-30.
20. Smith KD, Mezhir JJ, Bickenbach K, et al. Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Delta gamma (1)34.5 mutants of herpes simplex virus 1. Journal of Virology 2006; 80: 1110-1120.
21. Chou J, Chen JJ, Gross M, Roizman B. Association of a M(r) 90, 000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 1 34.5- mutants of herpes simplex virus 1. Proceedings of the National Academy of Sciences of the United States of America 1995; 92: 10516-10520.
22. Andreansky SS, He B, Gillespie GY, et al. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proceedings of the National Academy of Sciences of the United States of America 1996; 93: 11313-11318.
23. Chambers R, Gillespie GY, Soroceanu L, et al. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proceedings of the National Academy of Sciences of the United States of America 1995; 92: 1411-1415.
24. Markert JM, Malick A, Coen DM, Martuza RL. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 1993; 32: 597-603.
25. MacLean AR, Ul-Fareed M, Robertson L, Harland J, Brown SM. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. The Journal of General Virology 1991; 72(Pt 3): 631-639.
26. Rampling R, Cruickshank G, Papanastassiou V, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Therapy 2000; 7: 859-866.
27. Papanastassiou V, Rampling R, Fraser M, et al. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Therapy 2002; 9: 398-406.
28. Harrow S, Papanastassiou V, Harland J, et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Therapy 2004; 11: 1648-1658.
29. MacKie RM, Stewart B, Brown SM. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 2001; 357: 525-526.
30. Mace AT, Ganly I, Soutar DS, Brown SM. Potential for efficacy of the oncolytic herpes simplex virus 1716 in patients with oral squamous cell carcinoma. Head & Neck 2008; 30: 1045-1051.
31. Meignier B, Longnecker R, Mavromara-Nazos P, Sears AE, Roizman B. Virulence of and establishment of latency by genetically engineered deletion mutants of herpes simplex virus 1. Virology 1988; 162: 251-254.
32. Kemeny N, Brown K, Covey A, et al. Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Human Gene Therapy 2006; 17: 1214-1224.
33. Geevarghese SK, Geller DA, de Haan HA, et al. Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Human Gene Therapy 2010; 21: 1119-1128.
34. Hunter WD, Martuza RL, Feigenbaum F, et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. Journal of Virology 1999; 73: 6319-6326.
35. Sundaresan P, Hunter WD, Martuza RL, Rabkin SD. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. Journal of Virology 2000; 74: 3832-3841.
36. Markert JM, Liechty PG, Wang W, et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Molecular Therapy 2009; 17: 199-207.
37. Smith KD, Shao MY, Posner MC, Weichselbaum RR. Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application. Future Oncology 2007; 3: 545-556.
38. Shah AC, Parker JN, Gillespie GY, et al. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses. Gene Therapy 2007; 14: 1045-1054.
39. Mohr I. Neutralizing innate host defenses to control viral translation in HSV-1 infected cells. International Reviews of Immunology 2004; 23: 199-220.
40. Andreansky S, He B, van Cott J, et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Therapy 1998; 5: 121-130.
41. Parker JN, Gillespie GY, Love CE, Randall S, Whitley RJ, Markert JM. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proceedings of the National Academy of Sciences of the United States of America 2000; 97: 2208-2213.
42. Hellums EK, Markert JM, Parker JN, et al. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro-Oncology 2005; 7: 213-224.
43. Parker JN, Bauer DF, Cody JJ, et al. Oncolytic viral therapy of malignant glioma. Neurotherapeutics 2009; 6: 558-569.
44. Varghese S, Rabkin SD, Nielsen PG, Wang W, Martuza RL. Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. Clinical Cancer Research 2006; 12: 2919-2927.
45. Varghese S, Rabkin SD, Liu R, Nielsen PG, Ipe T, Martuza RL. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Therapy 2006; 13: 253-265.
46. Wong RJ, Patel SG, Kim S, et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Human Gene Therapy 2001; 12: 253-265.
47. Kaufman HL, Bines SD. OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncology 2010; 6: 941-949.
48. Harrington KJ, Hingorani M, Tanay MA, et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clinical Cancer Research 2010; 16: 4005-4015.
49. Kaufman HL, Kim DW, Deraffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Annals of Surgical Oncology 2009; 17: 718-730.
50. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. Journal of Clinical Oncology 2009; 27: 5763-5771.
51. Zhou G, Ye GJ, Debinski W, Roizman B. Engineered herpes simplex virus 1 is dependent on IL13Ralpha2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proceedings of the National Academy of Sciences of the United States of America 2002; 99: 15124-15129.
52. Campadelli-Fiume G, Amasio M, Avitabile E, et al. The multipartite system that mediates entry of herpes simplex virus into the cell. Reviews in Medical Virology 2007; 17: 313-326.
53. Carfi A, Willis SH, Whitbeck JC, et al. Herpes simplex virus glycoprotein D bound to the human receptor HveA. Molecular Cell 2001; 8: 169-179.
54. Connolly SA, Landsburg DJ, Carfi A, et al. Potential nectin-1 binding site on herpes simplex virus glycoprotein D. Journal of Virology 2005; 79: 1282-1295.
55. Manoj S, Jogger CR, Myscofski D, Yoon M, Spear PG. Mutations in herpes simplex virus glycoprotein D that prevent cell entry via nectins and alter cell tropism. Proceedings of the National Academy of Sciences of the United States of America 2004; 101: 12414-12421.
56. Debinski W. An immune regulatory cytokine receptor and glioblastoma multiforme: an unexpected link. Critical Reviews in Oncogenesis 1998; 9: 255-268.
57. Zhou G, Roizman B. Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor. Proceedings of the National Academy of Sciences of the United States of America 2006; 103: 5508-5513.
58. Menotti L, Cerretani A, Hengel H, Campadelli-Fiume G. Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. Journal of Virology 2008; 20: 10153-10161.
59. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer 2005; 5: 341-354.
60. Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. The Oncologist 2006; 11(Suppl 1): 4-12.
61. Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumour prevention. Nature Reviews Cancer 2006; 6: 204-216.
62. Melisko ME, Glantz M, Rugo HS. New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nature Clinical Practice Oncology 2009; 6: 25-33.
63. Menotti L, Cerretani A, Campadelli-Fiume G. A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors. Journal of Virology 2006; 80: 5531-5539.
64. Zhou G, Roizman B. Separation of receptor binding and pro-fusogenic domains of glycoprotein D of herpes simplex virus 1 into distinct interacting proteins. Proceedings of the National Academy of Sciences of the United States of America 2007; 104: 4142-4146.
65. Menotti L, Nicoletti G, Gatta V, et al. Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. Proceedings of the National Academy of Sciences of the United States of America 2009; 106: 9039-9044.
66. Fusco D, Forghieri C, Campadelli-Fiume G. The pro-fusion domain of herpes simplex virus glycoprotein D (gD) interacts with the gD N terminus and is displaced by soluble forms of viral receptors. Proceedings of the National Academy of Sciences of the United States of America 2005; 102: 9323-9328.
67. Krummenacher C, Supekar VM, Whitbeck JC, et al. Structure of unliganded HSV gD reveals a mechanism for receptor-mediated activation of virus entry. The EMBO Journal 2005; 24: 4144-4153.
68. Nakano K, Asano R, Tsumoto K, et al. Herpes simplex virus targeting to the EGF receptor by a gD-specific soluble bridging molecule. Molecular Therapy 2005; 11: 617-626.
69. Baek H, Uchida H, Jun K, et al. Bispecific adapter-mediated retargeting of a receptor-restricted HSV-1 vector to CEA-bearing tumor cells. Molecular Therapy 2011; 19: 507-514.
70. Kambara H, Okano H, Chiocca EA, Saeki Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Research 2005; 65: 2832-2839.
71. Mezhir JJ, Advani SJ, Smith KD, et al. Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses. Cancer Research 2005; 65: 9479-9484.
72. Advani SJ, Weichselbaum RR, Chmura SJ. Enhancing radiotherapy with genetically engineered viruses. Journal of Clinical Oncology 2007; 25: 4090-4095.
73. Advani SJ, Mezhir JJ, Roizman B, Weichselbaum RR. ReVOLT: radiation-enhanced viral oncolytic therapy. International Journal of Radiation Oncology, Biology, Physics 2006; 66: 637-646.
74. Tyminski E, Leroy S, Terada K, et al. Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Research 2005; 65: 6850-6857.
75. Otsuki A, Patel A, Kasai K, et al. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Molecular Therapy 2008; 16: 1546-1555.
76. Senzer NN, Kaufman H, Amatruda A, et al. Phase II clinical trial with a second generation, GM-CSF encoding, oncolytic herpesvirus in unresectable metastatic melanoma. Journal of Clinical Oncology (ASCO Meeting Abstract) 2009; 27: 9035.